Література - судинна біологія в клінічній практиці

Відео: Клінічна лабораторна діагностика у ветеринарній практиці

Відео: хвороба серця, ішемічна хвороба, задишка. Швидке зцілення. Микола Пейчев

1. Sherman DL. Exercise and endothelial function. Coron Artery Dis. 2000-11: 117-122.
2. Hambrecht R, Wolf A, Cielen S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med. 2000-342: 454-460.
3. Caterina R. Endothelial dysfunctions: common denominators in vascular disease. CurrOpin Lipidol. 2000-11: 9-23.
4. Contreras F, Rivera M, Vasquez, J, et al. Endothelial dysfunction in arterial hypertension. J Hum Hypertens. 2000-14 (suppl 1): S20-S25.
5. VanHoutie PM. Howto assess endothelial function in human blood vessels. J Hypertens. 1999-17: 1047-1058.
6. Ruschitzka F, Corti R, Noll G, Luscher TF. A rationale for treatment of endothelial dysfunction in hypertension. J Hypertens. 1999- 17 (suppl): S25-S35.
7. Danza JA, Cardillo C. Potential mechanisms of endothelial dysfunction in patients with essential hypertension. J Hypertens. 1998- 16 (suppl 8): S43-S48.
8. Intengan HD, Schiffrin EL. Role of endothelium in modulation of structural changes of small arteries in hypertension: effects of therapeutic intervention. J Hypertens. 1998: Додати 16 (suppl 8): S97-S101.
9. John S, Schmieder RE. Impaired endothelial function in arterial hypertension and hyp-erlipidemia: potential mechanisms and differences. J Hypertens. 2000,18: 363-374.
10. ChunTH, Itoh H, SaitoT, etal. Oxidative stress augments secretion of endothelium-derived relaxing peptides, С-type natriuretic peptide and adrenomedullin. J Hypertens. 2000-18: S7S-S80.
11. Adams MR, Kinlay S, Blake J, et al. Atherogenic lipids and endothelial dysfunction: mechanisms in the genesis of ischemic syndromes. Annu Rev Med. 2000-51: 149-167.
12. MclntyreM, BohrDF, Dominiczak AF. Endothelial function in hypertension. The role of superoxide anion. Hypertension. 1999-34: 539-545.
13. PepineCJ. Clinical implications of endothelial dysfunction. Clin Cardiol. 1998--21: 795-799.
14. Anderson TJ, Meredith IT, Charbonneau F. Endothelium-dependent coronary vaso-motion relates to the susceptibility of LDL to oxidation in humans. Circulation. 1996- 93: 16471650.
15. Pedrinelli R, DeN&rsquo-omoC, BandinelliS, etal. Transvascularalbumin leakage and forearm vasodilation to acetylcholine in essential hypertension. Am J Hypertens. 2000-13: 256-261.
16. KlobS, BoulournieA, Mulsch A. Aging and chronic hypertension decrease expression of rat aortic soluble guanylyl cyclase. Hypertension. 2000-35: 43-47.
17. Blankenship KA, Dawson CB, Aronoff CR, Dean WL. Tyrosine phosphorylation of human platelet plasma membrane CA2 * -atpase in hypertension. Hypertension. 2000-35: 103-107.
18. Suuaidi JA, Hamasaki S, Higano ST, et al. Long-term followup of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000,101: 948-954.
19. Celermajer DS. Howto measure endothelial functions in humans. Cardiol Rev. | 999-DEC: 1-7.
20. Yamakawa T, TanakaS, Numaguchi К, etal. Involvement of rho-kinase in Angiotensin
II induced hypertrophy of rat vascular smooth muscle cells. Hypertension. 2000-35 [-part 2J: 313-318.
21. HankeCJ, O&rsquo-Brien T, Pitchard KAetal. Inhibition of adrenal cell aldosterone synthesis by endogenous nitric oxide release. Hypertension. 2000-35 [part2]: 324-328.
22. Jackson WF. Ion channels and vascular tone. Hypertension. 2000-35 [part 2]: 173-178.
23. Smith IA, Lew RA, Shrimpton CN. A novel stable inhibitor of endopeptidases EC3.4.24.15 and 3.4.24.16 potentiates bradykinin-induced hypertension. Hypertension. 2000-35: 626-630.
24. ParissisJT, Venetsanou, KF, Kalantzi MV. Serum profiles of Granulocyte- Macrophage colony stimulating factor and CC chemokines in hypertensive patients with or without significant hyperlipidemia. Am J Cardiol. 2000-85: 777-779.
25. PezzaV, Bernardini F, Pezza E, etal. Study of supplemental oral L-arginine in hypertensives treated with enalapril plus hydrochlorothiazide. Am J Hypertens. 1998 Vol ll (No.10) Part 1: 1267-1269.
26. Watanabe C, Tomiyama H, Doba N. Effects of oral administration of L-arginine on renal function in patients with heart failure. J Hypertens. 2000- 18: 229-234.
27. Lind L, Granstam S, MillgardJ. Endothelium-dependent vasodilation in hypertension: a review. Blood Pressure. 2000-9: 4-15.
28. GoonasekeraCDA, Shah V, Rees DD, Dillon MJ. Vascular endothelial cell activation associated with increased plasma asymmetric dimethyl arginine in children and young adults with hypertension: a basis for atheroma? Blood Press. 2000-9: 16-21.
29. Caterina RD, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr. 2000-71 (suppl): 213S-223S.
30. Cotton S, Vadala A, Mangano MT, et al. Endothelium derived factors in microalbu-minuric and nonmicroalbuminuric essential hypertension. Am J Hypertens. 2000,13: 172- 176.
31. Kobayashi N, Нага K, Watanade S, et al. Effect of imidapril on myocardial remodeling in L-name induced hypertensive rats is associated with gene expression of NOS and ACEmRNA. Am J Hypertension. 2000-13: 199-207.
32. Hayashi S, Morishita R, Matsushita H. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells accompanied by induction of P53 and P21. Hypertension. 2000-35 [part 21: 237-243.
33. Gros R, Chorazyczewski J, Meek M. G-protein-coupled receptor kinase activity in hypertension. Hypertension. 2000-35: 38-42.
34. Dendorfer A, Wolfrum S, Schafer U, etal. Potentiation of the vascular response to kinins by inhibition of myocardial kininases. Hypertension. 2000-35: 32-37.
35. Haller H, Kettritz R, Luft F. Endothelial cell markers in vasculitis. Kidney Blood Press Res. 1998-21: 280-282.
36. Meerarani P, Ramadass P, Toborek M. Zinc protects against apoptosis of endothelial cells induced by linoleic acid and tumor necrosis factor. Am J Clin Nutr. 2000-71: 81
87.
37. Riser BL, Cortes P, Lee J. Modelling the effects of vascular stress in mesangial cells. CurrOpin Nephrol Hypertens. 2000-9: 43-47.
38. Petruzzelli L, Takami M, Humes D. Structure and function of cell adhesion molecules. Am) Med. 1999-106: 467-476.
39. Etzioni A. Integrins: the molecular glue of life. Hosp. Pract. 2000-March 15: 102-111.
40. Marul N, Offermann MK, Swerlicis R. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest. 1993,92: 1866-1874.
41. Price DT, Loscalzo]. Cellular adhesion molecules and atherogenesis. Am) Med. 1999-107: 85-97.
42. Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults. Implications for prevention from the pathobiologi-cal determinants of atherosclerosis in youth study. JAMA. 1999-281: 727-735.
43. EnosWF, Holmes RH, Beyer T. Coronary disease among United States soldiers killed in action in Korea [landmarkarticle]. JAMA. 1986-256: 2859-2862.
44. Assman C, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Eur Heart J. 1998-19 (suppl A): A2-A11.
45. Holman RL, McCill HC, Strong JP, Ceer JC. The natural history of atherosclerosis Am J Pathol. 1958-34: 209-235.
46. Stewart KG, Zhang Y, Davidge S. Aging increases PCHS-2-dependent vasoconstriction in rat mesenteric arteries. Hypertension. 2000-35: 1242-1247.
47. Chester AH, Boriand JAA. Chymase-dependent angiotensin II formation in human bloodvessels. J Hum Hypertens. 2000-14: 373-376.
48. McCord JM. The evolution offree radicals and oxidative stress. AmJ Med. 2000-1-08: 652-659.
49. Dhalla NS, Temsah RM, Netticadan T. The role of oxidative stress in cardiovascular diseases. J Hypertens. 2000-18: 655-673.
50. Wolf C. Free radical production and angiotensin. Curr Hypertens Reports. 2000-2: 167-173.
51. Somers MT, Harrison DC. Reactive oxygen species and the control of vasomotor tone. Curr Hypertens Reports. 1999-1: 102-108.
52. Usui M- Egashira K, Kitamoto S, et al. Pathogenic role of oxidative stress in vascular angiotensin converting enzyme activation in long-term blockade of nitric oxide synthesis in rats. Hypertension. 1999-34: 546-551.
53. Laakso J, Mervaala E, Himberg JJ, et al. Increased kidney xantine oxidoreductase activity in salt-induced experimental hypertension. Hypertension. 1998-32: 902906.
54. Romero JC, Reckelhoff JF Role of angiotensin and oxidative stress in essential hypertension. Hypertensin. 1999-34 (part 2): 943-949
55. Pedro-Botet J, Covas Ml, Martin S, Rubies-PratT. Decreased endogenous antioxidant enzymatic status in essential hypertension. J Hum Hypertens. 2000-14: 343-345
56. Greene EL, Verlarde V, Jaffa AA. Role of reactive oxygen species in bradykinin-induc-ed mitogen-activated protein kinase and C-FOS induction in vascular cells. Hypertension. 2000-35: 942-947.
57. Ma GE, Mason DP, Young DB Inhibition of vascular smooth muscle cell migration by elevation of extracellular potassium concentration. Hypertension. 2000-35: 948-951.
58. Lu G, Green L, Nagai T, Egan BM. Reactive oxygen species are critical in the oleic acid-mediated mitogenic signaling pathway in vascular smooth muscle cells. Hypertension. 1998-32: 1003-1010.
59. Orie N, Zidek W, Tepel M. Reactive oxygen species in essential hypertension and non-insulin-dependent diabetes mellitus. Am J Hypertens. 1999- 12: 1169-1174.
60. Koska J, Syrova D, Blazicek P, et al. Malondialdehyde, lipofuscin and activity of antioxidant enzymes during physical exercise in patients with essential hypertension.
J Hypertens. 1999-17: 529-S35.
61. ManciniGBJ, Henry GC, MacayaC. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation. 1996-94: 258-265.
62. Anderson TJ, Overhiser RW, Haber H, Charbonneau F, etal. A comparative study of four antihypertensive agents on endothelial function in patients with coronary disease [abstract]. J Am Coll Cardiol. 1998-31: 327A.
63. Hornig B, Arakawa N, Haussman D, Drexler H. Differential effects on quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation. 1998-98: 2842-2848.
64. Oosterga M, Voors AA, Buikema H. Functional effects of ACE-inhibitors on angiotensin I conversion in human vasculature. J Am Coll Cardiol. 1998-31 (suppl A): 239A.
65. Fabre J-E, Rivard A, Magnin M, Isner JM. Angiotensin converting enzyme inhibition with quinaprilat stimulates angiogenesis in a rabbit model with hindlimb ischemia [abstract]. J Am Coll Cardiol. 1998-31 (suppl A): 239A.
66. Nissen SE, Gurley JC, Booth DC, DeMariaAN. Intravascular ultrasound of the coronary arteries: current applications and future directions. Am J Cardiol. 1992-69: 18H-29H.
67. Pepine CJ. A symposium: endothelial function and cardiovascular disease: potential mechanisms and interventions. Am J Cardiol. 1998-82 (10A): 1S-64S.
68. Weir MR, Henrich WL. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. Curr Opin in Nephrol and Hypertens. 2000-9: 403-411.
69. Cohn) N. ACE-inhibition and vascular remodeling of resistance vessels. Vascular compliance and cardiovascular implications. Heart Disease. 2000-2: S2-S6.
70. Cohn JN. Vascular wall function as a risk marker for cardiovascular disease. J Hypertens. 1999- 17 (suppl S): S41 -S44.
71. McVeigh GE, Bratteli CW, Morgan DT, etal. Age related abnormalities in arterial compliance identified by pressure pulse contour analysis. Aging and arterial compliance. Hypertension. 1999-33 (6): 1392-1398.
72. Vlachopoulos C, O&rsquo-Rourke M. Diastolic pressure, systolic pressure or pulse pressure? Curr Hypertens Reports. 2000-2: 271-279.
73. Glaser SP, Arnett DK, McVeigh GE, et al. Vascular compliance and cardiovascular disease. A risk or a marker? Am J Hypertens. 1997 10: 1175-1189.
74. Glasser SP, Arnett DK, McVeigh GE, et al. The importance of arterial compliance in cardiovascular drug therapy. J Clin Pharmacol. 1998-38: 202-212.
75. ParkJB, Schiffrin EL. Effects of Antihypertensive therapy on hypertensive vascular disease. Curr Hypertens Reports. 2000-2: 280-288.
76. Franklin SS. Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance? Current Hypertens Reps. 2000-2: 253-259.
77. Buemi M, Corica F, Marino D, etal. Cardiovascular remodeling, apoptosisand drugs. Am) Hypertens. 2000-13: 450-454.
78. Cohn J. Pathophysiologic and prognostic implications of measuring arterial compliance in hypertensive disease. Prog Cardiovasc Dis. 1999-41 (6): 441-450.
79. O&rsquo-Rourke MF. Isolated systolic hypertension, pulse pressure and arterial stiffness as risk factors for cardiovascular disease. Curr Hypertens Rep. 1999-3: 204-211.
80. Bulpitt C), Cameron JD, Rajkumar C. The effects of age on vascular compliance in man: which are the appropriate measures? J Hum Hypertens. 1999- 13: 753-758.
81. Sharifi AM, Schiffrin EL. Apoptosis in vasculature of spontaneously hypertensive rats. Effect of an angiotensin converting enzyme inhibitor and a calcium channel antagonist. Am I Hypertens. 1998-11: 1108-1116.
82. Bank A), Kaiser DR. Smooth muscle relaxation. Effects on arterial compliance, Dis-tensibility, elastic module and pulse wave velocity. Hypertension. 1998-32: 356-359.
83. Arnett DK, Boland LL, Evans GW, et al. Hypertension and arterial stiffness: the atherosclerosis risk in communities study. Am J Hypertens. 2000-13: 317-323
84. Cockeroft JR, Webb D), Wilkinson IB. Arterial stiffness, hypertension and diabetes mellitus. J Hum Hypertens. 2000-14: 377-380.
85. Franklin SS. Aging and hypertension: the assessment of blood pressure indices in predicting coronary heart disease.) Hypertens. 1999,17 (suppl 5): S29-S36.
86. Baumbach CL, Chillon JM. Effects of angiotensin-converting enzyme inhibitors on cerebral vascular structure in chronic hypertension. J Hypertens. 2000- 18 (suppl): S7-S11.
87. Kuller LH, Sutton-Tyrrell K, Matthews KA. Blood pressure levels and measurement of Subclinical vascular disease. J Hypertens. 1999- 17 (suppl 5): S15-SI9.
88. MalekAM, AlperSL, IzumoS. Hemodynamic shear stress and its role in atherosclerosis. JAMA. 1999-282 (21): 2035-2042.
89. Resnick N, Yahau H, SchubertS, etal. Signaling pathways in vascular endothelium activated by shear stress: relevance to atherosclerosis. CurrOpin in Lipidol. 2000- 11: 167177.
90. Kannel WB. Elevated blood pressure as a cardiovascular risk factor. Am J Cardiol. 2000-85: 251-255.
91. Smulyan H, Safar ME. The diastolic blood pressure in systolic hypertension. Ann Intern Med. 2000-132-233-237.
92. Staessen JA, Gasowski J, Wang JC, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000-355: 865-872.
93. Starmans-Kool, MJF, Kleinjans, HAJ, Lustermans, FAT, etal. Treatment of elderly patients with isolated systolic hypertension with isosorbide dinitrate in an asymmetric dosing schedule. J Hum Hypertens. 1998-12: 557-561.
94. Black HR, Kuller LH, O&rsquo-Rourke MF, etal. The first report of the systolic and pulse pressure (SYPP) working group. ] Hypertens. 1999- 1 7 (suppl5): S3-S14.
95. Blacher J, Staessen JA, Cirerd X, et al. Pu Ise pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med. 2000-160: 1085-1089.
96. Safar ME. Epidemiological aspects of pulse pressure and arterial stiffness. J Hypertens. 1999- 17 (suppl 5): S37-S40.
97. Busse R, Fleming I. Nitric oxide, nitric oxide synthase, and hypertensive vascular disease. Curr Hypertens Reports. 1999-1: 85-88.
98. StamlerJ. Nitric oxide in the cardiovascular system. Coron Artery Dis. 1999- 10: 273-276.
99. Soma M, Nakayama T, Kanmatsuse К. N itric oxide synthase gene polymorphism and its influence on cardiovascular disease. CurrOpin Nephrol Hypertens. 1999-8: 83-87.
100. Maxwell AJ, Cooke JP. The role of nitric oxide in atherosclerosis. Coron Artery Dis. 1999-10: 277-286.
101. Zou AP, Cowley AW. Role of nitric oxide in the control of renal function an salt sensitivity. Curr Hypertens Reports. 1999- 1: 178-186.
102. Klahr S. The role of L-arginine in hypertension and nephrotoxicity. Opin Nephrol Hypertens. 1998-7: 547-550.
103. Bhagat K, Vallance P. Effects of cytokines on nitric oxide pathways in human vasculature. Current Opinion in Nephrology and Hypertension. 1999-8: 89-96.
104. Campbell DJ. Bioactive angiotensin peptides other than angiotensin II receptor antagonists. Epstein M, and Brunner HR (eds): Angiotension II ReceptorAnt-agonists. Hanley and Belfus, Philadelphia, 2001..
105. Gimbrone MA, Topper JN. Biology of the vessel wall: endothelium. In Chien KR (ed): Molecular Basis of Cardiovascular Disease. Philadelphia, WB Saunders Company, 1999, pp 331-348.
106. Libby P, Hansson GK, Rober JS. Atherogenesis and inflammation. In Chien KR (ed): Molecular Basis of Cardiovascular Disease. Philadelphia, WB Saunders, 1999, pp 349-366.
107. PanzaJA. Nitricoxide in hypertension, pp 158-165. InOparil S, Weber MA (eds): Hypertension: A Companion to Brenner and Rector&rsquo-s: The Kidney. Philadelphia, WB Saunders, 2000., pp 158-165.
108. Oparil S, Weber MA. Hypertension: A Companion to Brenner and Rector&rsquo-s: The Kidney. Philadelphia, WB Saunders, 2000..
109. Fabiani ME, Dinh DT, Nassis L, Johnston Cl. Angiotensin-converting enzyme: basic properties, distribution and functional role. In Weber MA (eds): Hypertension: A Companion to Brenner and Rector&rsquo-s: The Kidney. WB Saunders, 2000., pp 90-97.
110. Stary HC. Atlas of Atherosclerosis: Progression and Regression. New York and London, Parthenon, 1999..
111. Kannel WB, Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996-275: 1 572-1 576.
112. Weber MA, Smith DHC, Neutel JM, CraettingerWF. Arterial properties of early hypertension. J Hum Hypertens. 1991-5: 417-423.
113. Dzau VJ, Gibbons GH. Vascular remodeling: mechanisms and implications. J Cardiov-asc Pharmacol. 1993-21 (suppl 1): S1-S5.
114. Dzau, VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993-153: 937-942.